Literature DB >> 11228464

Investigation of the ototoxic effects of interferon alpha2A on the mouse cochlea.

M U Akyol1, S Sarac, G Akyol, A Atac, A Poyraz, E Belgin, E Turan.   

Abstract

This prospective randomized study investigates the possible toxic effects of interferon (IFN) alpha2A on the mouse cochlea. Thirty-six albino Swiss mice that were randomly assigned to 3 groups underwent baseline auditory brain stem response testing bilaterally to objectively assess baseline hearing levels. The first group received a single dose of 50,000 units, and the second group received 100,000 units of IFN-alpha2A intraperitoneally, whereas the third group was given no medication. Repeat auditory brain stem response testing revealed a significant rise in mean baseline peak equivalent sound pressure level thresholds in the groups that received IFN (P < 0.001). Histologically, the cochleae of mice that received IFN had a decreased number of fibroblasts in the spiral limbus, as well as prominent cytoplasmic vacuolation of these cells, compared with control animals. Loss of hair cells was not observed. It is possible that reversible biochemical and metabolic changes in the cochlea, rather than morphologic abnormalities, manifest IFN ototoxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11228464     DOI: 10.1067/mhn.2001.112312

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  4 in total

1.  Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.

Authors:  Savita Jain; Vandana Midha; Ajit Sood
Journal:  Indian J Gastroenterol       Date:  2011-09

2.  Effect of interferon treatment on hearing of patients with chronic hepatitis C.

Authors:  Abdulrahman Hagr; Dima Jamjoom; Faisal M Sanai; Waleed Al Hamoudi; Ayman A Abdo; Ahmed Al-Arfaj
Journal:  Saudi J Gastroenterol       Date:  2011 Mar-Apr       Impact factor: 2.485

3.  A case of hearing loss associated with pegylated interferon and ribavirin treatment ameliorated by prednisone.

Authors:  Vu Le; Ted Bader; Javid Fazili
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-11-25

Review 4.  A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity.

Authors:  Christine Little; Maura K Cosetti
Journal:  Laryngoscope       Date:  2021-01-27       Impact factor: 2.970

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.